Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pest Manag Sci ; 70(4): 559-65, 2014 Apr.
Article in English | MEDLINE | ID: mdl-23650150

ABSTRACT

BACKGROUND: Higher rates of diseases transmitted from insects to humans led to the increased use of organophosphate insecticides, proven to be harmful to human health and the environment. New, more effective chemical formulations with minimum genetic toxicity effects have become the object of intense research. These formulations include larvicides derived from plant extracts such as dillapiol, a phenylpropanoid extracted from Piper aduncum, and from microorganisms such as spinosad, formed by spinosyns A and D derived from the Saccharopolyspora spinosa fermentation process. This study investigated the genotoxicity of dillapiol and spinosad, characterising and quantifying mutation events and chromosomal and/or mitotic recombination using the somatic mutation and recombination test (SMART) in wings of Drosophila melanogaster. RESULTS: Standard cross larvae (72 days old) were treated with different dillapiol and spinosad concentrations. Both compounds presented positive genetic toxicity, mainly as mitotic recombination events. Distilled water and doxorubicin were used as negative and positive controls respectively. CONCLUSION: Spinosad was 14 times more genotoxic than dillapiol, and the effect was found to be purely recombinogenic. However, more studies on the potential risks of insecticides such as spinosad and dillapiol are necessary, based on other experimental models and methodologies, to ensure safe use.


Subject(s)
Dioxoles/toxicity , Insecticides/toxicity , Macrolides/toxicity , Mutagens/toxicity , Allyl Compounds , Animals , DNA Damage , Drosophila melanogaster/drug effects , Drosophila melanogaster/genetics , Drug Combinations , Larva/drug effects , Larva/genetics , Mutagenicity Tests , Recombination, Genetic
2.
An Acad Bras Cienc ; 85(2): 585-94, 2013.
Article in English | MEDLINE | ID: mdl-23828338

ABSTRACT

Noni, a Hawaiian name for the fruit of Morinda citrifolia L., is a traditional medicinal plant from Polynesia widely used for the treatment of many diseases including arthritis, diabetes, asthma, hypertension and cancer. Here, a commercial noni juice (TNJ) was evaluated for its protective activities against the lesions induced by mitomycin C (MMC) and doxorrubicin (DXR) using the Somatic Mutation and Recombination Test (SMART) in Drosophila melanogaster. Three-day-old larvae, trans-heterozygous for two genetic markers (mwh and flr3 ), were co-treated with TNJ plus MMC or DXR. We have observed a reduction in genotoxic effects of MMC and DXR caused by the juice. TNJ provoked a marked decrease in all kinds of MMC- and DXR-induced mutant spots, mainly due to its antirecombinagenic activity. The TNJ protective effects were concentration-dependent, indicating a dose-response correlation, that can be attributed to a powerful antioxidant and/or free radical scavenger ability of TNJ.


Subject(s)
Antimutagenic Agents/pharmacology , Beverages , Fruit/chemistry , Morinda/chemistry , Mutagenicity Tests/methods , Animals , DNA Damage/drug effects , Drosophila melanogaster/cytology , Drosophila melanogaster/drug effects , Mitomycin/pharmacology , Theophylline/analogs & derivatives , Theophylline/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...